Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.44 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23174782 | 0.98 | PDK2 (0.43) | PDK2AGBL2GABRDGABRA1GABRB2 | |
| SCHEMBL12986210 | 0.84 | PDK2 (0.45) | PDK2GABRDGABRA1GABRB2GABRA4 | |
| SCHEMBL10203215 | 0.84 | NR1H4 (0.38) | PDK2ACHEHTTGAACSF1R | |
| SCHEMBL23174803 | 0.82 | PDK2 (0.47) | PDK2LMNA | |
| SCHEMBL9980439 | 0.77 | POLB (0.44) | GAA | |
| SCHEMBL13172345 | 0.77 | KDM4E (0.39) | GABRDGABRA1GABRB2GABRA4ACHE | |
| SCHEMBL22781872 | 0.77 | PDK2 (0.43) | PDK2 | |
| SCHEMBL31456905 | 0.77 | HTT (0.42) | PDK2ARHTTLMNAGAA | |
| SCHEMBL2186892 | 0.76 | EPHX2 (0.38) | PDK2GABRDGABRA1GABRB2GABRA4 | |
| SCHEMBL20703152 | 0.76 | ACHE (0.43) | AGBL2GABRDGABRA1GABRB2GABRA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761082-A | Azepane derivatives | 日本化学药品株式会社 | 2022-07-15 | — | — | CN | disclosed |
| WO-2021065898-A1 | AZEPAN DERIVATIVE | 日本ケミファ株式会社 | 2021-04-08 | — | — | WO | disclosed |
| EP-2694509-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES | PFIZER LTD (GB) | 2016-05-18 | — | — | EP | disclosed |
| EP-2694509-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN-RELATED KINASES | PFIZER LTD (GB) | 2016-05-18 | — | — | EP | disclosed |
| WO-2016051193-A1 | COMPOUNDS USEFUL AS CSF1 MODULATORS | REDX PHARMA PLC (GB) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016051193-A1 | COMPOUNDS USEFUL AS CSF1 MODULATORS | REDX PHARMA PLC (GB) | 2016-04-07 | — | — | WO | disclosed |
| US-9163021-B2 | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | PFIZER LIMITED (GB) | 2015-10-20 | — | — | US | disclosed |
| US-9163021-B2 | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | PFIZER LIMITED (GB) | 2015-10-20 | — | — | US | disclosed |
| US-9163021-B2 | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors | PFIZER LIMITED (GB) | 2015-10-20 | — | — | US | disclosed |
| US-20150250785-A1 | Tropomyosin-Related Kinase Inhibitors | PFIZER LIMITED (GB) | 2015-09-10 | — | — | US | disclosed |
| WO-2014053965-A1 | TROPOMYOSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2014-04-10 | — | — | WO | disclosed |
| EP-2694509-A1 | PYRROLO [2, 3 -D]PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | Pfizer Limited (GB) | 2014-02-12 | — | — | EP | disclosed |
| CN-103534257-A | Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases | PFIZER | 2014-01-22 | — | — | CN | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| WO-2012137089-A1 | PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | PFIZER LIMITED (GB) | 2012-10-11 | — | — | WO | disclosed |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | PFIZER LIMITED (GB) | 2012-10-11 | — | — | US | disclosed |
| WO-2012137089-A1 | PYRROLO [2, 3 -D] PYRIMIDINE DERIVATIVES AS INHIBITORS OF TROPOMYOSIN- RELATED KINASES | PFIZER LIMITED (GB) | 2012-10-11 | — | — | WO | disclosed |
| WO-2011150201-A2 | AZOLYL AMIDE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20100076087-A1 | METHODS OF REDUCTION OF INTERPATIENT VARIABILITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076087-A1 | METHODS OF REDUCTION OF INTERPATIENT VARIABILITY | TPMT, GUSB, CYP2D6 | PDK2 2058/4885AGBL2 135/4885GABRD 938/4885 |
| US-20150250785-A1 | Tropomyosin-Related Kinase Inhibitors | MUSK, TPM3, TNNI3 | PDK2 554/4885AGBL2 2130/4885GABRD 1211/4885 |
| US-20120258950-A1 | PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS | DMPK, DTYMK, MUSK | PDK2 305/4885AGBL2 2260/4885GABRD 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.